Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of Q-1802 combined with standard therapy in gastrointestinal tumors
CTR20231483Phase 2Active
- Sponsor
- Qiyu Bio
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of q-1802 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Qiyu Bio. Started Jul 2023; status: active.
02
Drugs
q-1802
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20231483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231483.